A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/17/2002	WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002	WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002	WO2002036605A9 Estrone-derivatives having cytoprotective activity
10/17/2002	WO2002036108A3 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
10/17/2002	WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002	WO2002021932A3 Animal feed, feed additive and therapeutic agent against intestinal inflammation
10/17/2002	WO2002019213A3 Method for treatment of migraine using pde5 inhibitors
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002	WO2002008420A3 A method of down-regulating gene expression
10/17/2002	WO2002007772A3 Improved oral dosage formulations
10/17/2002	WO2001098344A3 Angiogenesis-modulating compositions and uses
10/17/2002	WO2001096283A9 Hiv integrase inhibitors
10/17/2002	WO2001091736A3 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
10/17/2002	WO2001083463A1 Oxadiazole derivatives having anticancer effects
10/17/2002	WO2001077378A3 Diagnosis of diseases associated with dna adducts
10/17/2002	WO2001074404A3 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor
10/17/2002	WO2001070664A3 Lipoxin analogs and methods for the treatment of periodontal disease
10/17/2002	WO2001060847A9 Avirulent, immunogenic flavivirus chimeras
10/17/2002	WO2001058241A9 Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
10/17/2002	WO2001057015A9 INTERNAL 1,15-LACTONES OF FLUPROSTENOL AND RELATED PROSTAGLANDIN F2α ANALOGS AND THEIR USE IN THE TREATMENT OF GLAUCOMA AND INTRAOCULAR HYPERTENSION
10/17/2002	WO2001055370A9 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
10/17/2002	WO2001049279A3 Use of steroidal alkaloids to reverse multidrug resistance
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	WO2001040497A3 Method for obtaining nucleic acids from an environment sample
10/17/2002	WO2001000138B1 Use of hydroxydiphenyl ether class of chemicals, as exemplified by triclosan, as an antimalarial and identification of fatty acid synthesis as its target
10/17/2002	US20020152498 Mutant plant
10/17/2002	US20020152481 Genetic engineering; qualitative analysis
10/17/2002	US20020151732 Estrogen receptors
10/17/2002	US20020151724 Such as 1-((4-methoxybenzoyl-D-phenylglycinyl))-4-((isopropylamino)methyl)piperidine hydrochloride as anticoaggulants useful in the treatment of cardiovascular disorders such as thrombosis
10/17/2002	US20020151717 Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
10/17/2002	US20020151715 Imidazole derivatives
10/17/2002	US20020151693 Nucleic acid catalysts with endonuclease activity
10/17/2002	US20020151689 Method of killing target cells in harvested cell populations with one or more immuno-toxins
10/17/2002	US20020151677 Replikins and methods of identifying replikin-containing sequences
10/17/2002	US20020151601 1-(2-haloethyl)-1-nitroso-(cyclohexyl)urea derivatives are useful for reducing acute allograft rejection by recipient
10/17/2002	US20020151600 Administering a formulation containing a sesquiterpene alcohol, particularly cedrol, having a boiling atleast 250 degree C. to a person in need for regulation of autonomic nerve activity
10/17/2002	US20020151599 Formulations having an antiviral action
10/17/2002	US20020151598 Bronchodilating compositions and methods
10/17/2002	US20020151597 Formoterol, or a derivative; long term storage stability
10/17/2002	US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002	US20020151594 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
10/17/2002	US20020151593 Water-soluble creatine monohydrate formulations and process for their preparation
10/17/2002	US20020151592 Long term administration of L-arginine, L-lysine or salts, and a polypeptide precursor which enhance the level of endogenous nitric oxide or intermediates in the NO induced relaxation pathway in the host
10/17/2002	US20020151591 4-oxo-1,4-tetrahydro-1,5- naphthyridine-3-carboxamide derivative useful in treatment of disorders associated with cognition impairment including, Alzheimer's, vascular dementia, Parkinson's disease etc
10/17/2002	US20020151590 Compositions and methods for regulating circadian rhythyms
10/17/2002	US20020151589 Levodopa (l-dopa) ethyl ester, carbidopa or benserazide, a filler, a disintegrant, and a lubricant tablets used to treat Parkinson's disease
10/17/2002	US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002	US20020151587 15-fluoro prostaglandins as acular hypotensives
10/17/2002	US20020151586 Antidiabetic agents
10/17/2002	US20020151585 Carbamate compounds for use in preventing or treating movement disorders
10/17/2002	US20020151583 Prevention of liver cancer by administration of simvastatin
10/17/2002	US20020151582 Inhibiting proteasomal chymotrypsin-like activity
10/17/2002	US20020151581 Glucose and lipid lowering compounds
10/17/2002	US20020151578 Formulation based on lipoic acid, process for its production and the use of this formulation for oral administration of lipoic acid
10/17/2002	US20020151577 Antiparasitic composition for the treatment and protection of pets
10/17/2002	US20020151576 Inhibiting sodium/hydrogen exchanger activity and the n-type calcium channel with imidazoline derivatives
10/17/2002	US20020151575 Heterocyclic topoisomerase poisons
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151573 Anticancer agents
10/17/2002	US20020151572 Nitric oxide synthase (NOS); alone or in combination with another active agent for the treatment of psoriasis, an antiinflammatory, an analgesic, a cognition enhancer or sleep disorder treatment
10/17/2002	US20020151569 Peroxisome Proliferator Activated Receptors (PPARs) antagonists 4-oxo-5-thiazolidine acetamide derivatives
10/17/2002	US20020151568 Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity
10/17/2002	US20020151566 Phosphodiesterase 4 inhibitors
10/17/2002	US20020151565 Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
10/17/2002	US20020151564 Methods for inhibiting immunostimulatory DNA associated responses
10/17/2002	US20020151563 Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
10/17/2002	US20020151562 Compositions and methods for treating allergic fungal sinusitis
10/17/2002	US20020151561 Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity
10/17/2002	US20020151560 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/17/2002	US20020151559 Analgesic combination of oxycodone and 6-MNA
10/17/2002	US20020151558 Triazolo compounds as MMP inhibitors
10/17/2002	US20020151557 CRF receptor antagonists and methods relating thereto
10/17/2002	US20020151555 Pyrimidine matrix metalloproteinase inhibitors
10/17/2002	US20020151554 Cyclin-dependent kinase inhibitors such as (4-Amino-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-thiazolyl) (2,3-dihydro-1,4-benzodioxin-6-yl)methanone for treatment of breast, lung, colon, and prostate cancer/tumors
10/17/2002	US20020151553 Such as 4-(4-chlorophenyl)1-(3-(5-cyano-5H-dibenzo(a,d) cycloheptene-5-yl)propyl)piperidin-4-ol for treatment of diseases associated with aberrant leukocyte recruitment and/or activation
10/17/2002	US20020151552 Novel compounds
10/17/2002	US20020151551 Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
10/17/2002	US20020151549 Such as 3-(6-bromo-2-methylimidazo(1,2-a)pyridin-3-yl)-1H-pyrazol-1-yl 2-methyl-5-nitrophenyl sulfone; useful as phosphatidylinositol-3-kinase (PI3K) inhibitors and antitumor agents
10/17/2002	US20020151547 Substituted phenyl-piperidine methanone compounds
10/17/2002	US20020151545 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and metastasis inhibitors in treating cancer
10/17/2002	US20020151544 Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide
10/17/2002	US20020151543 Compositions and methods employing R (-) fluoxetine and other active ingredients
10/17/2002	US20020151542 Method for determining whether a compound is an insulin receptor kinase activator
10/17/2002	US20020151541 For treatment of respiratory tract diseases
10/17/2002	US20020151540 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
10/17/2002	US20020151538 Azepin-2-one derivatives useful for treating Alzheimer's disease
10/17/2002	US20020151537 Calcium channel blocker agent selected from diphenylalkylamines, benzothiazepines or dihydropyridines; useful for reducing fibrosis in elastic tissue of human male penis
10/17/2002	US20020151536 Substituted azetidinone is used as sterol absorption inhibitor and a fibric acid derivative selected from fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate etc
10/17/2002	US20020151535 Heterocyclic 1,2,4-oxadiazole or oxazole ring containing propanohydroxamic acids useful as antiscarring agent
10/17/2002	US20020151533 Complexes of L-cysteine, N-acetyl L-cysteine, N-(2-mercaptopropionyl)glycine, L-2-oxothiazolidine-4-carboxylate with a metal (copper, magensium or selenium), used for treating chronic glaucoma,
10/17/2002	US20020151531 Administering to a female of child bearing age over a period of 28 consecutive days a first phase of from 18 to 21 daily dosage units of a progestational agent, and a second phase of from 1 to 7 daily dosage units of an antiprogestin agent
10/17/2002	US20020151530 Administering to a woman, undergoing estrogen replacement therapy for treating homonal deficiences, continuously and uninterruptedly, a therapeutic effective amount of both estrogen and a non-aromatizing androgen in daily dosage
10/17/2002	US20020151529 Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
10/17/2002	US20020151528 Use of 2alpha-methyl-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
10/17/2002	US20020151527 Administration of a sensory regimen in an amount effective to downregulate the activity of hypothalamus-pituitary-adrenal(HPA) axis in combination with adminstration of an anti-acne drug
10/17/2002	US20020151521 Packaged condomes containing spermicides, microbiocides and viricides, an acid buffer solution, a wound healing and diffusion impedance compound selected from dextran sulfate, chondroitin sulfate, pentosan polysulfate and a hyaluronate
10/17/2002	US20020151520 Method of promoting angiogenesis
10/17/2002	US20020151519 Administering therapeutic compounds useful for treating autoimmune disorders and inflammatory conditions are selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analog
10/17/2002	US20020151518 Oligonucleotide mediated specific sytokine induction and reduction of tumor growth in a mammal

1 ... 5677 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 ... 7860